Abstract
Here we report that targeting casein kinase 1-α1 (CSNK1α1) is a potential novel treatment strategy in multiple myeloma (MM) therapy distinct from proteasome inhibition. CSNK1α1 is expressed in all the tested MM cell lines and patient MM cells, and is not altered during bortezomib-triggered cytotoxicity. Inhibition of CSNK1α1 kinase activity in MM cells with targeted therapy D4476 or small hairpin RNAs triggers cell G0/G1-phase arrest, prolonged G2/M phase and apoptosis. D4476 also induced cytotoxicity in bortezomib-resistant MM cells and enhanced bortezomib-triggered cytotoxicity. CSNK1α1 signaling pathways include CDKN1B, P53 and FADD; gene signatures involved included interferon-α, tumor necrosis factor-α and LIN9. In addition, reduction of Csnk1α1 prevents cMYC/KRAS12V transformation of BaF3 cells independent of interleukin-3. Impartially, reducing Csnk1α1 prevented development of cMYC/KRAS12V-induced plasmacytomas in mice, suggesting that CSNK1α1 may be involved in MM initiation and progression. Our data suggest that targeting CSNK1α1, alone or combined with bortezomib, is a potential novel therapeutic strategy in MM. Moreover, inhibition of CSNK1α1 may prevent the progression of monoclonal gammopathy of undetermined significance to MM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Palumbo A, Anderson K . Multiple myeloma. N Engl J Medi 2011; 364: 1046–1060.
Anderson KC . New insights into therapeutic targets in myeloma. Hematology Am Soc Hematol Educ Program 2011; 2011: 184–190.
Kane RC, Bross PF, Farrell AT, Pazdur R . Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508–513.
Field-Smith A, Morgan GJ, Davies FE .. Ther Clin Risk Manag 2006; 2: 271–279.
Kuehl WM, Bergsagel PL . Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456–3463.
Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026–1035.
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904–917.
Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001; 414: 768–773.
Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G et al. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 2011; 470: 409–413.
Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA 2012; 109: 9545–9550.
Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M . The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 2005; 17: 675–689.
Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res 2010; 16: 1856–1864.
Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692–1700.
Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Wurl PU et al. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie 2005; 28: 508–514.
Huart AS, MacLaine NJ, Meek DW, Hupp TR . CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem 2009; 284: 32384–32394.
Huart AS, MacLaine NJ, Narayan V, Hupp TR . Exploiting the MDM2-CK1alpha protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth. PLoS One 2012; 7: e43391.
Meek DW, Knippschild U . Posttranslational modification of MDM2. Mol Cancer Res 2003; 1: 1017–1026.
Alappat EC, Feig C, Boyerinas B, Volkland J, Samuels M, Murmann AE et al. Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell 2005; 19: 321–332.
Beyaert R, Vanhaesebroeck B, Declercq W, Van Lint J, Vandenabele P, Agostinis P et al. Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. J Biol Chem 1995; 270: 23293–23299.
Desagher S, Osen-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A et al. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 2001; 8: 601–611.
Zhao Y, Qin S, Atangan LI, Molina Y, Okawa Y, Arpawong HT et al. Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis. J Biol Chem 2004; 279: 30844–30849.
Hu Y, Zheng M, Gali R, Tian Z, Topal Gorgun G, Munshi NC et al. A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J 2013; 3: e156.
Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009; 48: 603–614.
Rena G, Bain J, Elliott M, Cohen P . D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 2004; 5: 60–65.
Tillement V, Lajoie-Mazenc I, Casanova A, Froment C, Penary M, Tovar D et al. Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization. Exp Cell Res 2008; 314: 2811–2821.
Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 2008; 68: 5658–5668.
Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226–231.
Reichert N, Wurster S, Ulrich T, Schmitt K, Hauser S, Probst L et al. Lin9, a subunit of the mammalian DREAM complex, is essential for embryonic development, for survival of adult mice, and for tumor suppression. Mol Cell Biol 2010; 30: 2896–2908.
Sana TR, Janatpour MJ, Sathe M, McEvoy LM, McClanahan TK . Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. Cytokine 2005; 29: 256–269.
Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005; 24: 3397–3408.
Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260–264.
Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997; 90: 4062–4070.
Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 2014; 123: 706–716.
Zhu J, Shibasaki F, Price R, Guillemot JC, Yano T, Dotsch V et al. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell 1998; 93: 851–861.
Russell M, Lange-Carter CA, Johnson GL . Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase kinase kinase (MEKK1). J Biol Chem 1995; 270: 11757–11760.
Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, Cabrelle A et al. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. Clin Cancer Res 2012; 18: 1888–1900.
Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698–1707.
Teoh G, Tai YT, Urashima M, Shirahama S, Matsuzaki M, Chauhan D et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 2000; 95: 1039–1046.
Oberg K . The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992; 3: 35–41.
Blade J, Esteve J . Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients? Med Oncol 2000; 17: 77–84.
Bergsagel PL, Kuehl WM . Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333–6338.
Acknowledgements
We thank Mei Zheng for performing the histological sections; Reddy Gali, who is part of Harvard Catalyst grant member, for his conduction in microarray analysis; the Microarray and the Flow Cytometry Core Facilities at Dana-Farber Cancer Institute for technical support. This study was supported in part by National Institutes of Health Grants P50-100707, P01-78378 and RO1-50947. KCA is an American Cancer Society Clinical Research Professor.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Hu, Y., Song, W., Cirstea, D. et al. CSNK1α1 mediates malignant plasma cell survival. Leukemia 29, 474–482 (2015). https://doi.org/10.1038/leu.2014.202
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.202
This article is cited by
-
Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma
Leukemia (2019)
-
Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma
Cell Death Discovery (2019)
-
Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
Journal of Hematology & Oncology (2017)